What are you searching for?

10.01.2022 | Tracker

Product Launch Tracker: Pre-Christmas approvals drive HCPs conversations

CREATION Team photo of Research Associate Paul Cranston By Paul Cranston and Tomi Shobande

Every month, CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.

———

Throughout December 2021 we tracked the global conversations of 3,357 HCPs who posted 5,228 English-language Twitter posts about the launches and approvals of new products.

 

In December, HCPs discussed the approval of several treatments including three new COVID-19 treatments, an injectable alternative to daily pills for HIV prevention, and a small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (LDL-C). The week leading up to Christmas saw a significant spike in conversation, mainly driven by HCPs sharing their thoughts on the FDA’s approval of two antiviral COVID-19 treatments for emergency use.

HCPs spoke positively of the approval of Pfizer’s Paxlovid (nirmatrelvir co-packaged with ritonavir) and MSD’s Molnupiravir, seeing both treatments as a step forward in the fight against COVID-19. However, some HCPs were restrained in their excitement, noting that widely available testing and free provision of the treatment would be required for these treatments to have a major impact.

Earlier this month, HCPs also displayed excitement for another COVID-19 treatment, AstraZeneca’s Evusheld, which gained Emergency Use Authorization (EUA) from the FDA on 9 December. HCP’s heralded the monoclonal antibody treatment as a great alternative to vaccination for immunocompromised patients and those with a history of severe adverse reactions to a COVID-19 vaccine.

As well as discussing new COVID-19 treatments, HCPs showed an active interest in the FDA’s approval of ViiV Healthcare’s new treatment, Apretude (cabotegravir extended-release injectable suspension), for use in at-risk adults and adolescents to reduce the risk of HIV.  As the first injectable treatment for HIV pre-exposure prophylaxis, HCPs marked it as an important milestone for preventing HIV without a daily pill. 

Lastly, HCPs also welcomed the FDA’s approval of Novartis’ Leqvio (inclisiran) as the first and only siRNA therapy to lower LDL-C. Most HCPs were pleased with the news, however, some were critical of how long it took the FDA to approve the treatment.

The three most shared links from HCPs discussing product launches in December were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.

Methodology

  • Using CREATION Pinpoint® the English-language Twitter conversations of HCPs globally discussing new pharmaceutical product launches and drug approvals between 1 December and 31 December 2021 were analysed in order to discover which new product launches HCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by HCPs in their Twitter conversations.
  • Between 1 December and 31 December 2021, there were 5,228 HCP mentions of new pharmaceutical product launches and drug approvals from 3,357 unique HCP authors from around the world.

View the latest product launch and archived trackers here

 

View all articles >

CREATION Team photo of Research Associate Paul Cranston

Meet the Authors

Paul Cranston

Paul analyses the online conversations of HCPs to provide insights for pharmaceutical companies about what HCPs think. With a background in international development, he is passionate about using data to reveal the unmet needs in healthcare communities.

In his free time, Paul can often be found either writing songs on his guitar or kicking a ball around on a football field.

Tomi Shobande

Tomi is passionate about building relationships with clients and helping them attain their business goals and objectives. With a background in law, international development and human rights, she is keen on bringing about a positive difference around healthcare inequities and shaping health outcomes for all groups.

Tomi enjoys spending good quality time with friends and family. She also is passionate about travel and learning different cultures and histories along the way.

Suggested next


Product Launch Tracker: FDA’s Pfizer vaccine approval continues to drive HCPs conversations

01.10.2021 | Article

Product Launch Tracker: FDA’s Pfizer vaccine approval continues to drive HCPs conversations

Discover which new drug approvals and launches HCPs are talking about

By Francesca Gan and Chawanzi Chintu

top 50 pharma tracker banner

02.06.2021 | Article

HCPs discuss accessibility of COVID-19 treatments globally.

Regarding vaccine efficacy and safety, HCPs shared how medical professionals have been study

By Maria Aguirre

View all articles >